Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Male Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer
Interventions: BIOLOGICAL: oblimersen sodium|DRUG: doxorubicin hydrochloride|DRUG: docetaxel|BIOLOGICAL: filgrastim|BIOLOGICAL: pegfilgrastim|PROCEDURE: therapeutic conventional surgery|OTHER: pharmacological study|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)